Trial Profile
A RANDOMIZED, PARALLEL-GROUP, OPEN-LABEL, PLACEBO CONTROLLED STUDY OF THE EFFECT OF OAP-189 ON THE PHARMACOKINETICS AND PHARMACODYNAMICS OF METFORMIN IN DIABETIC SUBJECTS.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 03 Nov 2020
Price :
$35
*
At a glance
- Drugs OAP 189 (Primary) ; Metformin
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; Therapeutic Use
- 11 Aug 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 09 May 2011 Planned End Date changed from 1 Jun 2011 to 1 Jul 2011 as reported by ClinicalTrials.gov.
- 14 Mar 2011 Planned end date changed from 1 Jan 2011 to 1 Jun 2011 as reported by ClinicalTrials.gov.